Accellta Grants Rights for its Feeder-free Stem Cell Culture Medium to Thermo Fisher Scientific

HAIFA, Israel, June 8, 2015 /PRNewswire/ --

Stem Cell Company Accellta announced today that it has granted worldwide non-exclusive rights to Thermo Fisher Scientific for manufacture and distribution of proprietary cell culture medium and ancillary products and methods.

Accellta's patented technology is an important addition to stem cell growth, expansion and manufacturing technologies. It was designed by Accellta to enable homogeneous growth of stem cell production by enabling culturing of the cells in feeder-free, serum-free and xeno- free media.

Accellta's approach for culturing of pluripotent and differentiated stem cells in feeder-free conditions has been experimentally validated in numerous stem cell lines, including embryonic and induced human pluripotent stem cells.

Dr. Itzchak Angel, Accellta Chairman and Chief Executive Officer, said: "Enabling consistent and robust cell growth and expansion, while reducing the costs of stem cell products, are the key technological challenges the stem cell industry is facing today, and some of the main goals of Accellta's revolutionary technologies. We are delighted to license this technology to Thermo Fisher and believe this agreement will maximize the global reach of our solutions and make a significant impact on the robust and cost-effective use of stem cell-based products for research and regenerative medicine."

Accellta was established in 2012 by the Technion and AMIT (the Alfred Mann Institute at the Technion). The company offers a range of revolutionary solutions for better affordability and quality of stem cell culturing and for developing specialty media and stem cell lines and services. Accellta's unique solutions are the result of over 15 years of pioneering research and development at the Stem Cell Center of the Rappaport Faculty of Medicine at the Technion - Israel Institute of Technology. Accellta has also granted licenses to other multinational life-science companies, including STEMCELL Technologies, Ajinomoto, and Miltenyi Biotec.

Accellta is currently focused on creating strategic partnerships with biopharma and stem cell companies for developing large-scale and cost-effective tailor-made manufacturing processes for cell products. The company also plans to expand the use of its technologies for potential therapeutic applications of stem cells.

About  Accellta 

Accellta develops, manufactures and markets a range of revolutionary solutions for better affordability and quality of stem cell culturing and for developing specialty cell culture tools, services and cell lines. Accellta's technologies are the result of over 15 years of pioneering research and development at the Stem Cell Center in the Technion's Rappaport Faculty of Medicine. Accellta operates a state-of-the-art manufacturing facility, laboratories and offices in Haifa, Israel. http://www.accellta.com

Contact

Dr. Itzchak Angel, Chairman & CEO
Tel. +972-4-8291070
E-mail. [email protected]

SOURCE Accellta

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED